Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

A strange thing happened weeks before the Food and Drug Administration approved the first treatment made with CRISPR gene editing, an all-but cure for certain patients with sickle cell disease.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

But amid all the fervor and history-making lies a few teething issues. Namely, even with the improved specificity CRISPR-Cas9 has brought to gene-editing, accidental, off-target effects still happen.

CRISPR can be used to make other types of edits too, such as increasing or decreasing the effects of a gene temporarily. Regardless of the type of editing, the process generally remains limited to ...

We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.’s nomination to be HHS ...

Both CRISPR systems reduced serum PCSK9 protein to undetectable levels. NanoCas also demonstrated 10% to 40% editing of the dystrophin gene across the quadricep, calf, and heart muscle in a ...

as it is the first approval for a CRISPR-based gene-editing therapy in the world. Developed in collaboration with Vertex Pharmaceuticals VRTX, Casgevy was approved in late 2023/early 2024 for two ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...